Monday, July 18, 2016 9:21:41 AM
"...using strategic partnerships"!!!
http://finance.yahoo.com/news/seethruequity-initiates-coverage-cellectar-biosciences-130000249.html
THEY CONCLUDED AS I DID:
..."Cellectar's lead candidate using PDC is CLR-131, a Phase 1 candidate for the treatment of multiple myeloma.
Cellectar intends for PDC to serve as a platform technology, which can be used to address many cancer types. We would expect the company to pursue a strategy in which it demonstrates the effectiveness of the platform with initial candidates covering a diverse group of payloads. Then we would expect Cellectar to advance new indications though strategic partnerships with larger pharmaceutical companies better equipped to fully fund new drug development. In our view, Cellectar is a speculative company in the biotechnology sector with the potential to develop and commercialize an impactful new cancer targeting and payload delivery technology in the large and growing market for oncology therapeutics," commented Ajay Tandon, CEO of SeeThruEquity. "We initiate coverage on Cellectar with a price target of $7.44.":
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123735723
Expect press releases, starting THIS week.
Recent CLRB News
- Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 08/26/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:15:38 PM
- Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq • GlobeNewswire Inc. • 08/23/2024 09:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:15:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:45:19 AM
- Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 08/13/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:47 PM
- UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 09:15:14 PM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2024 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 10:45:24 AM
- Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months • GlobeNewswire Inc. • 07/23/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:45:16 AM
- Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million • GlobeNewswire Inc. • 07/22/2024 10:40:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:15:21 PM
- Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape • GlobeNewswire Inc. • 06/27/2024 10:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:17 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM